千红制药(002550) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 608,218,905.42, representing a 10.14% increase compared to CNY 552,220,533.56 in the same period last year[5] - Net profit attributable to shareholders decreased by 32.98% to CNY 85,946,847.70 from CNY 128,247,521.34 year-on-year, primarily due to a high base effect from last year's compensation received for land acquisition[8] - The company reported a decrease in operating income of CNY 58.01 million compared to the previous year, mainly due to a reduction in non-operating income[9] - Net profit for Q1 2023 was CNY 83,549,827.62, a decrease of 33.67% from CNY 125,796,128.32 in Q1 2022[22] - The company reported a total comprehensive income of CNY 83,505,000.50 for Q1 2023, compared to CNY 126,448,478.68 in Q1 2022, indicating a decline of 33.94%[22] Cash Flow - The net cash flow from operating activities was negative at CNY -28,080,310.76, a decrease of 130.53% compared to CNY 91,973,048.64 in the previous year[5] - The total cash inflow from operating activities was CNY 717,640,499.05, an increase from CNY 535,125,534.57 in the previous period, representing a growth of approximately 34%[23] - The net cash outflow from operating activities was CNY -28,080,310.76, compared to a net inflow of CNY 91,973,048.64 in the same period last year[23] - Cash inflow from investment activities totaled CNY 51,340,000.00, slightly up from CNY 49,488,572.06 in the previous year[23] - The net cash outflow from investment activities was CNY -107,460,996.87, a significant decrease from a net inflow of CNY 5,965,581.15 in the previous period[23] - Cash inflow from financing activities was CNY 200,000,000.00, an increase from CNY 106,677,500.00 in the previous year, marking an increase of approximately 87%[24] - The net cash flow from financing activities was CNY 199,080,789.21, compared to CNY 105,710,814.66 in the same period last year[24] - The total cash and cash equivalents at the end of the period were CNY 470,466,348.14, down from CNY 819,179,841.19 in the previous year[24] - The company experienced a negative impact of CNY -2,329,800.95 from exchange rate fluctuations on cash and cash equivalents[24] - The cash outflow for purchasing goods and services was CNY 580,833,369.71, significantly higher than CNY 285,911,340.92 in the previous year[23] Assets and Liabilities - The company's total assets increased by 9.28% to CNY 3,066,259,293.87 from CNY 2,805,938,488.48 at the end of the previous year[5] - The total assets of the company as of Q1 2023 were CNY 3,066,259,293.87, compared to CNY 2,805,938,488.48 at the end of Q1 2022, reflecting a growth of 9.27%[19] - The company's total liabilities increased to CNY 549,346,015.40, up 47.43% from CNY 372,530,210.51 in the previous year[19] - The equity attributable to shareholders of the parent company rose to CNY 2,536,256,250.79, an increase of 3.51% from CNY 2,450,354,230.21 in Q1 2022[19] - The company’s total non-current assets amounted to CNY 1,000,000,000.00, reflecting a stable investment in long-term growth[17] Research and Development - Research and development expenses grew by 83.32% compared to the beginning of the period, indicating increased investment in R&D projects[9] - R&D expenses increased significantly to CNY 20,590,742.37, up 83.56% from CNY 11,231,856.32 in the previous year[21] - The company received approval for the clinical trial of its new drug QHRD107, which will be tested in combination with Venetoclax and/or Azacitidine for treating acute myeloid leukemia (AML)[15] - The company plans to conduct a Phase II clinical trial for QHRD107, indicating ongoing investment in research and development[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 100,348, with the largest shareholder holding 19.96% of the shares[12] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0672, down from CNY 0.1026 in the same period last year[22] - The first phase of the employee stock ownership plan "Qianhong Pharmaceutical No. 1" has completed its lock-up period as of March 30, 2023[15] Inventory and Borrowings - Inventory levels rose by 32.16% as a result of increased stockpiling of key raw materials[9] - Inventory rose significantly to CNY 709,033,420.43 from CNY 536,483,390.67, marking an increase of approximately 32.1%[17] - The company's short-term borrowings increased by CNY 200.73 million, primarily due to the need for working capital for production[9]